ALENDRONATE VERSUS PLACEBO FOR OSTEOPENIA IN HIV

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。A5163是一项II期随机、双盲、安慰剂对照研究，用于治疗HIV相关性骨密度下降。80名受试者(每只手臂40名，女性27名，男性13名)将接受为期48周的盲法研究治疗，此外还补充钙/维生素D。这项研究将考察每周服用阿伦磷酸钠对接受稳定的抗逆转录病毒治疗(ART)的HIV感染者腰椎和髋部骨密度的影响，同时每天补充钙/维生素D。该研究还将评估阿仑磷酸钠在该人群中的安全性和耐受性。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. A5163 is a phase II, randomized, double-blind, placebo-controlled study of the bisphosphonate alendronate for the treatment of HIV-associated decreased bone mineral density (BMD). 80 subjects (40 per arm, 27 female and 13 male in each) will receive blinded study treatment for 48 weeks, in addition to a calcium/vitamin D supplement. This study will examine the effect of weekly alendronate on lumbar spine and hip BMD in HIV-infected subjects receiving stable antiretroviral therapy (ART), in addition to daily calcium/vitamin D supplement. The study also will assess the safety and tolerability of alendronate in this population.